Richard B. Lipton, M.D.
Scientific Advisory Board
Richard B. Lipton, M.D.
Richard B. Lipton, M.D., is the Edwin S. Lowe Professor and Vice Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine. Dr. Lipton earned his medical degree at the University of Chicago Pritzker School of Medicine. After a medical internship at Northwestern Memorial Hospital, he completed his neurology residency and clinical neurophysiology fellowship at the Albert Einstein College of Medicine. He also completed a fellowship in neuroepidemiology at Columbia University. He is a diplomate of the American Board of Psychiatry and Neurology and a fellow of the American Academy of Neurology. His research focuses on cognitive aging, Alzheimer’s disease and migraine headaches. He is the Principal Investigator of the Einstein Aging Study, an NIH funded Program Project, and several R01s. His research focuses on risk factors and biomarkers of cognitive decline and Alzheimer’s disease. His recent studies examine cognitive aging across the lifespan with an emphasis on the effects of pain and stress on brain function. His headache research focuses on the epidemiology of migraine and on clinical trials. His epidemiologic studies have evaluated trigger factors for headache attacks and risk factors for headache progression. Dr. Lipton has published more than 500 original articles, many with trainees. He is a 3 time winner of the H.G. Wolff Award for excellence in headache research from the American Headache Society and the Enrico Greppi award from the European Headache Federation. Dr. Lipton is co-Director of the Montefiore Headache Center, an interdisciplinary subspecialty center focused on headache, patient care, research and education. Dr. Lipton holds leadership positions in several professional societies. He is a Past-President of the American Headache Society (AHS). He serves on the editorial boards of several journals, including Neurology. He has written 11 books. Dr. Lipton enjoys mentoring medical students, residents, PhD students and fellows.
John Krystal, M.D.
Scientific Advisory Board
John Krystal, M.D.
Head of Scientific Advisory Board and Co-inventor of Yale IP. Dr. Krystal is the Chair of the Department of Psychiatry, Robert L. McNeil, Jr., Professor of Translational Research, and Professor of Neurobiology at the Yale University School of Medicine. His research has focused on disturbances in amino acid (glutamate, GABA) signaling in psychiatric disorders. He is Chief of Psychiatry at Yale-New Haven Hospital, Director of the NIAAA Center for the Translational Neuroscience of Alcoholism, Director of the Clinical Neuroscience Division of the VA National Center for PTSD and Co-Director of the Neuroimaging Core of the Consortium to Alleviate PTSD. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published more than 400 papers and reviews on the neurobiology and treatment of schizophrenia, alcoholism, post-traumatic stress disorder, and depression. His research program unites psychopharmacology, neuroimaging, and molecular genetics. Dr. Krystal has received a numerous national and international awards for his research.
Gerard Sanacora, M.D.
Scientific Advisory Board
Gerard Sanacora, M.D.
Dr. Sanacora is Professor and Director of the Yale Depression Research Clinic. Dr. Sanacora’s work is concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders. He completed an NIH sponsored Medical Scientist Training Program at the State University New York at Stony Brook, earning his Ph.D. in Physiology and Biophysics in 1992 and his M.D. degree in 1994. He completed his residency and an NIH funded Neuroimaging Scientist Training Program Fellowship at Yale. Dr. Sanacora’s laboratory has provided several seminal studies highlighting the contributions of the glutamatergic neurotransmitter system to the pathophysiology and treatment of mood and anxiety disorders. Reflecting his contributions to the field, he received the Anna-Monkia Stiftung international award for the investigation of the biological substrate and functional disturbances of depression in 2009 and the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the ACNP in 2011. Dr. Sanacora was elected a Fellow of the American College of Neuropsychopharmacology in 2012.
David Spiegel, M.D., Ph.D.
Scientific Advisory Board
David Spiegel, M.D., Ph.D.
Dr. Spiegel is Professor of Chemistry and Pharmacology at Yale University. He is founder of the Spiegel Research Group at Yale, which is focused on scientific research on novel therapeutic strategies for the treatment of the most challenging diseases, including autoimmune disorders, cancer and infectious diseases, as well as for promoting longevity. Notably, the Spiegel laboratory was the first to discover a strategy for extracellular protein degradation called Molecular Degraders of Extracellular Proteins (MoDE), aimed at selectively removing soluble proteins that are implicated in a broad range of antibody-mediated diseases. The discovery formed the basis for a proprietary drug discovery platform, which was later licensed to and eventually acquired by Biohaven. As an entrepreneur, Dr. Spiegel has successfully bridged the worlds of academic research and commercial drug development to benefit the lives of patients. Harnessing his discoveries at Yale, he has founded or co-founded several pharmaceutical and biotech companies, including Allied-Bristol Life Sciences, Kleo Pharmaceuticals, Kymera Therapeutics, Magnet Biomedicine, Revel Pharmaceuticals, Moda Pharmaceuticals and Virality Diagnostics. Dr. Spiegel is the recipient of numerous awards for his scientific and medical research including, DARPA HEALR Award, NIH Director’s New Innovator Award, Department of Defense Era of Hope Scholar Award, the Ellison Medical Foundation New Scholar Award in Aging Research, the Novartis Early Career Award in Organic Chemistry, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, the Alfred P. Sloan Foundation Fellowship, and others.